Screening of different yeast species showed that they are able to synthesize hydroxymethylglutaryl-CoA (HMGCOA) reductase inhibitors. Crude methanol extracts and the purified inhibitors from Pichiu labacensis and Cundida cariosilignicola were tested for their biological activity on the solubilized microsomal HMGCoA reductase from Chinese hamster ovary cells. Identification of the inhibitors was studied by thin layer chromatography, high pressure liquid chromatography and mass spectroscopy.
Introduction
HMGCoA reductase has been extensively studied because it is rate-limiting in sterol biosynthesis [l] . Mevalonate, the product of the reaction catalysed by this enzyme, is not only a sterol precursor, but also a precursor of some other important isoprenoid intermediates, such as ubiquinone, dolichols, prenilated proteins, and isopentenyl t-RNAs [2] . Fungal secondary metabolites, such as mevinolin and related compounds, are potent competitive HMGCoA reductase inhibitors [3, 4] . Most authors have limited their searches for inhibitor producers to soil microorganisms, particularly bacteria and filamentous fungi [5] . When screening of cultures from the Fungal Culture Collection of the National Institute of Chemistry (MZKI), the ability to produce HMGCoA reductase inhibitors was found to be wide-spread among fungi originating from different taxonomic groups and habitats [6] . Besides others, different lignicolous basidiomycetous fungi produced HMGCoA reductase inhibitors [7, 8] , but yeasts have not been investigated. So far, only the susceptibility of yeast strains to HMGCoA reductase inhibitors has been reported [9, 10] , but not the ability to produce them. Accordingly, the present paper reports the results of screening yeasts for the production of a HMGCoA reductase inhibitor.
Materials and methods

Organisms and fermentation conditions
92 yeast strains were from the Fungal culture collection MZKI of the National Institute of Chemistry, Ljubljana.
All cultures were maintained on beer wort and potato glucose agar slants at 30°C for 7 days. The yeast cells (5 X IO7 ml-') were suspended in 25 ml of water and 5 ml used to inoculate 50 ml of growth medium. The preliminary screening used a growth medium described by Alberts et al. [3] and, subsequently, medium I. 5% of growth medium was used as an inoculum for medium II or III, used for producing the inhibitor.
During screening, growth was for one day and subsequently 2 days. The productive phase was initially 5 days and, during optimization, from 6-9 days. A rotary shaker was used at 200 rpm and 30°C for all tests. The composition of the media was as follows.
Medium I: 1 .O g beech sawdust, 1.0 g ground corncobs, 1.0 g soy meal, 4.5 g glucose, 5.0 ml glycerol, 0.1 g ammonium molybdate.
Medium II: 5.0 g glucose, 2.0 g brewery yeast, 3.0 g tomato paste, 2.0 g oatmeal, 1.0 g sodium acetate, 0.5 g (NH&S• ,, 0.2 g KI-I,PO,, 1.0 ml solution of trace elements [3] .
Medium III: 10.0 g glycerol, 1.0 g wheat straw, cut to l-2 cm segments, 4.0 g oatmeal, 1.5 g tomato paste, 4.0 g brewery yeast, 5.0 g glucose, 2.0 g sodium acetate, 0.5 g (NH4j2S04 and 1 ml of trace elements solution [3] . All media were diluted to 100 ml with tap water and pH was adjusted to 7.0 with 0.1 M NaOH.
Analyses of the Hh4GCoA reductase inhibitor
The pH values of the media (II or III) were adjusted to 3.0 and an equal volume of methanol added. Extraction was performed for 12 h at 200 rpm and 30°C. The samples were filtered, and the inhibitor converted to the sodium salt and lactonized [l I]. During screening, the extracts were initially analysed by TLC as described previously [6] , followed by HPLC analyses [12] . The pH value of the fermentation broth was adjusted to pH 7.7 with 1 M NaOH; methanol extraction was performed for 12 h at 200 rpm and 30°C. The filtered samples were analysed by HPLC (Knauer) on a 0.25 km, 250 X 4 mm Spherisorb column, using as the elution solvent 20 mM phosphate buffer pH 7.7, acetonitrile (63:37, v/v> with a flow rate of 0.7 ml per min at 40°C and a UV detector at 237 nm.
Lovastatin as Mevacor tablets (Merck) was dissolved in a water-methanol mixture (I : 1 v/v> at pH 3.0 or pH 7.7 and used as a standard.
Isolation of the inhibitor
Preparative TLC plates (Merck Silica gel 60 F,,,, 2 mm) were used for the isolation of the HMGCoA reductase inhibitor. Chromatograms were developed 3 times in a solvent system of dichloromethane, ethylacetate (7:3, v/v) . For detecting the inhibitor(s), the plates were stained with iodine vapours or visualized under UV light at 254 nm.
Identification of the inhibitor
The isolated compounds were further analyzed by mass spectrometry on an Auto SpecEQ FAB + Magnet BpI mass spectrometer (VKB Analytica, Manchester, UK). Mass spectra were compared with the standard sample of lovastatin.
HMGCoA reductase assay
Biological activities of isolated compounds from two yeasts Candida cariosilignicola and Pichia labacensis were tested with HMGCoA reductase obtained from Chinese Hamster Ovary (CHO-Kl) cells. Maintenance of the cells and the enzyme preparation were as described earlier [7, 13] . To 25 ~1 of the solubilized enzyme preparation, the following were added: (i) 25 ~1 of NADPH regenerating system, consisting of IO mg NADP+, 10 mg dithiotreitol, 100 ~1 of 0.5 M glucose-6-phosphate and 350 U of glucose-6-phosphate 1 -dehydrogenase in 1 ml of 0.05 M K-phosphate buffer, pH 7.4, (ii) 10 ~1 of the potential inhibitor at between lo-" M and 10e9 M. The amount of radiolabelled mevalonic acid produced from DL-(3-i4C)HMGCoA was assessed as described by Have1 et al. [14] .
Proteins were determined as described by Lowry et al. [15l with bovine albumin as the reference standard.
Results and discussion
Screening of yeast strains
Previous screening of MZKI filamentous ascomycetous and basidiomycetous fungal cultures revealed producers of HMGCoA reductase inhibitors [6] . In addition, 95 yeast strains of 15 genera and 35 species were tested. Preliminary analyses by TLC gave positive results for 44% of these yeasts, but this was confirmed for only 10% of them by HPLC analyses. Yeast strains with yields of HMGCoA reductase inhibitors from 0.5 to 3 pg ml-' were of the following genera: Candida, Debaryomyces, Kluyueromyces, Pichia, Saccharomyces, Saccharomycodes, Zygosaccharomyces, and Yarrowia, none of which had previously been reported as HMGCoA inhibitor producers.
Among all previously tested basidiomycetes, wood fungi were found to be especially good producers of HMGCoA reductase inhibitor, with the best being white rot fungi of the genus Pleurotus [8] . These observations led us to select two potentially interesting yeast species, which gave higher yields of presumed HMGCoA reductase inhibitor. Candida cariosilignicofa (MZKI K-l 38) is a known decayed wood dweller, named and described in 1980 [ 161 and Pichia fabacensis (MZKI K-100), isolated from waste in a pulp factory [17] .
Experiments with Pleurotus spp. showed pH control and slow use of carbon sources to be essential. The latter can be achieved by partial substitution of Table I Yields of inhibitor (pg/ml) of fichia labacensis (K-100) and 
Candida cariosilignicola
II: Medium with added lignin and cellulose materials (A).
111: Medium with added lignin and cellulose materials (B).
A and B contain different ratios of the same components.
glucose as the carbon source. During submerged fermentations with the two selected yeast strains, different lignin-and cellulose-containing substrates were tested and the inhibitor yields compared with the results obtained using media without such additions. Prolongation of the growth and productive phases with media to which lignin ingredients were added, resulted in higher yields of the inhibitor (Table l) , a pronounced beneficial effect on the inhibitor production being achieved by the following: cut wheat straw, ground corncobs and beech wood particles or sawdust in amounts of l-2%.
Isolation and identification of the HMGCoA reductase inhibitor
Methanol extracts of the fermentation broth were submitted to HPLC as described above. The acid form of the standard lovastatin preparation appeared at a retention time of 7.30 min. Methanol extracts of both yeast strains gave similar HPLC profiles (Fig.   1) .
The inhibitors were isolated by TLC. The presumed inhibitor of P. labacensis gave the same Rf value (0.57) as that of the lovastatin standard; while extracts from C. cariosilignicofa gave both a spot with the same Rf as the standard and an additional spot with a slightly higher Rf (Fig. 2) . The isolated compounds were further analysed by mass spectrometry and the mass spectra were compared with that of the lovastatin standard. Mass spectra yielded a parent ion (m') at m/z 405 and 423 corresponding to the lactone form and acid form of lovastatin respectively, and is in accordance with previous reports on the structure of HMGCoA reductase inhibitors [3, 18] . Table 2 shows the results of the inhibition of the solubilized HMGCoA reductase obtained from CHO-Kl.
Inhibition of the HMGCoA reductase
The isolated compounds of both selected strains had an inhibitory effect on solubilized HMGCoA reductase of CHO-Kl cells. Table 2 also shows that K-100 is more potent than K-138, since a 50% inhibition of reductase activity is given by 4 x lo-" M K-100 and by 6 X lo-* M K-138. These results are consistent with studies of the most probable compounds. Thin layer chromatography ( Fig. 2) and mass spectra analyses revealed that the K-l 38 sample is either a mixture of two active compounds with one more potent than the other, but both related to the lovastatin structure, or K-l 38 is a mixture of an active inhibitor and some impurity without inhibitory effects. On the other Table 2 Inhibitory effect of compounds isolated from the extracts of P.
hbacensis ( hand, TLC and mass spectra of K-100 indicated a structural resemblance of the isolated compound to lovastatin. In our study, Pichia labacensis and Candidu cariosilignicola were compared, as these two yeasts are similar with respect to the ubiquinone system, lignin degrading abilities, and some other fermentative characteristics [16] . The results show that these two yeast species are also comparable with respect to HMGCoA reductase inhibitor production. This is in agreement with the assumption that taxonomically related microorganisms are also physiologically similar and able to produce similar secondary metabolites h181.
